You are here

Article Text

Article menu
Download PDFPDF
Case Reports: Rare disease
Sweet’s syndrome in the setting of newly initiated risankizumab therapy for pre-existing psoriasis
  1. Fadwa Ahmed1,
  2. Samuel Masur2,
  3. Shaza Ben Khadra3 and
  4. Muhammad Baig4
  1. 1Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA
  2. 2Department of Pediatrics and Internal Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA
  3. 3Department of Pathology, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA
  4. 4Department of Medicine, Miriam Hospital, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA
  1. Correspondence to Fadwa Ahmed; fadwa_ahmed{at}brown.edu

Abstract

Sweet’s syndrome (acute febrile neutrophilic dermatosis) is a rare disorder of unclear aetiology characterised by painful cutaneous lesions, sometimes accompanied by systemic symptoms. It has been associated with several autoimmune conditions, drugs, malignancies and infections, though many cases are idiopathic. We describe a case of Sweet’s syndrome in a 49-year-old man with pre-existing psoriasis following recent initiation of risankizumab therapy. There are very few reported cases of Sweet’s syndrome in association with psoriasis and no existing reports in association with an IL-23 inhibiting medication. Further investigation of the potentially overlapping immunologic pathways implicated in cutaneous reactions to biologic agents and autoimmune conditions such as psoriasis may yield insights into the pathogenesis of such conditions and guide advancements in the rapidly evolving field of targeted biologic therapies.

  • dermatology
  • skin
  • immunology
  • unwanted effects / adverse reactions
  • biological agents

https://doi.org/10.1136/bcr-2021-246774

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors FA wrote the initial draft and revised the draft. SM assisted in writing and revised the draft. SBK provided histopathology images and revised the draft. MB supervised and revised the draft.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.